Posted by Michael Wonder on 26 Sep 2019
Pfizer’s leukaemia therapy Besponsa to get insurance benefit
26 September 2019 - The government said it would grant insurance benefit to Pfizer’s leukaemia treatment Besponsa (ingredient: inotuzumab ozogamicin).
The drug is reimbursable when indicated for a secondary or tertiary remission induction therapy in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
The Ministry of Health and Welfare on Wednesday held a meeting of the Health Insurance Policy Deliberation Committee and decided on the revision of the list of reimbursable medicines and reimbursement rate caps.
The revised list will be effective from 1 October.
